JPH01226812A - Remedy for bovine adiponecrosis - Google Patents

Abstract

PURPOSE:To obtain a remedy for bovine adiponecrosis, enabling the effective digestion and absorption of lipid while preventing the hydrogenation of the lipid in the rumen of cattle, by coating the surface of a lipid particle containing eicosapentaenoic acid with a hardened coating film of a protein. CONSTITUTION:A granular lipid (e.g. fish oil or chlorella oil) containing >=5wt.% of eicosapentaenoic acid in the fatty acid composition is mixed with a protein coating film (e.g. casein or collagen) to cover the surface of the granular lipid and with a hardener (e.g. glutaraldehyde) to harden the protein coating film. Preferably, an emulsifier is added in the mixing of the above components. The amounts of the lipid, emulsifier, protein and hardener are 5-90wt.%, 0.01-3wt.%, 10-95wt.% and 0.01-5wt.%, respectively. The mixture is dried to obtain the objective powder, which is orally administered to cattle as it is or in the form mixed with feed, etc.

Description

[Detailed Description of the Invention] [Field of Industrial Application] The present invention relates to a therapeutic agent for treating fat necrosis by effectively digesting and absorbing lipids in the rumen of cattle without undergoing hydrogenation. It is.

[Conventional technology]

Bovine fat necrosis occurs frequently in Japanese black cattle, and causes degenerative necrosis in the abdominal fat tissue, especially in the disc colon, rectum, and perirenal fat, forming hard masses. It is known as a disease in which the mass compresses and narrows the intestinal tract and pregnant uterus, causing secondary gastrointestinal symptoms and miscarriage.

The cause of its occurrence is degenerative necrosis of adipose tissue caused by lipolytic enzymes (Ribelin, W. E. et al.
(1960): J, Am, Vert, Sci.
136.135), fat melting and chemical changes due to increased abdominal temperature during fever (Hofland).

S, et al (1953): Prac, 15
th, Int, Yet, Congr.

Stockholm, 642), saturation of body fat by feeding saturated fatty acids in feed (Herting, D.
C, et al (1959): Fed, Proc.
18.529), but the mechanism of its development has not yet been elucidated.

Until now, studies have been carried out on the therapeutic effect of beef fat necrosis, and the administration of coix seed (Journal of Japan-European Society, 32.331-340 (197
9)) Administration of soysterol (Nutritional Physiology Research Journal, 2
7゜131 (1983)) and the administration of safflower oil (Japan-European Society Journal, 32゜331-340 (1979)), but no significant therapeutic effect has been found.

[Problem to be solved by the invention]

When cows develop fat necrosis, even if the symptoms are not severe, their mission of breeding can be adversely affected, resulting in large economic losses, and the development of effective therapeutic agents is desired.

An object of the present invention is to provide a therapeutic agent for bovine fat necrosis that has high therapeutic efficacy and safety and can be produced at low cost, in order to meet the above-mentioned needs.

[Means to solve the problem]

The present invention comprises a particulate lipid containing 5% by weight or more of eicosapentaenoic acid in the fatty acid composition, a protein film that coats the surface of this particulate lipid, and a hardening agent that hardens this protein film. It is a treatment for fat necrosis.

The therapeutic agent for beef fat necrosis of the present invention is for treating beef fat necrosis by avoiding hydrogenation of lipids containing eicosapentaenoic acid in the rumen of cattle and allowing them to be effectively digested and absorbed. This provides a high therapeutic effect.

Eicosapentaenoic acid has high physiological activity, but
When using this as a therapeutic agent, cattle undergo a digestive process in which lipids are partially hydrogenated in the rumen, digested in the abomasum, and absorbed in the small intestine. It undergoes hydrogenation and loses its activity.

In the present invention, eicosapentaenoic acid, which has physiological activity in living organisms, is contained in order to avoid the hydrogenation reaction in the abomasum and to efficiently cause digestion and absorption from the abomasum onwards. The lipid is granulated and protected by coating it with a hardened protein film.

The lipid used in the present invention contains 5 eicosapentaenoic acids.
It is a lipid that contains more than % by weight, and natural oils and fats include fish oil,
Chlorella oil, concentrated oil obtained from these oils, synthetic glyceride esters containing eicosapentaenoic acid, etc. can be used. Furthermore, fat-soluble substances such as vitamins A, D, E, etc. or phytosterols may be added to the lipid. These lipids are used in granulated form.

The protein used in the present invention is a coating agent for preventing lipids from being hydrogenated in the rumen of cattle, and examples thereof include casein, collagen, gelatin, albumin, and wheat protein. can be used. In addition, carbohydrates, gums, and the like having coating properties can also be blended and used. These coating agents are used to coat the lipid particles, and are made into a hardened film using a hardening agent.

The hardening agent used in this invention 1 hardens the protein used in the coating so that it will not be decomposed by microorganisms in the cow's rumen, and contains glutaraldehyde, formaldehyde, -Methylglutaraldehyde, tannic acid, alum, etc. can be exemplified, and one or more of these can be used.

In the present invention, lipids can be easily granulated by emulsifying them at a temperature higher than their melting point. At this time, if emulsification is performed in a protein solution using an emulsifier, it is possible to convert the lipid into particles and simultaneously coat the lipid with a protein film. A hardening agent is then added to the emulsion and allowed to react, thereby curing the protein coating to form a cured film.

The emulsifier used in the present invention may be any agent for emulsifying lipids and proteins, such as glycerin fatty acid ester, propylene glycol fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, lecithin, etc. One or more types can be used.

In the present invention, the blending ratio of each component is 5 to 90% by weight of lipid, 0.01 to 3% by weight of emulsifier, and 10 to 9% by weight of protein.
5% by weight of the hardener and 0.01 to 5% by weight of the hardening agent.

The therapeutic agent for beef fat necrosis of the present invention is obtained by adding lipid in which an emulsifier has been dissolved in advance to protein dissolved in warm water to emulsify it, homogenizing it, adding a hardening agent, and drying it by a spray drying method or the like. It can be manufactured using Drying methods include spray drying, freeze drying, and vacuum drying, but spray drying is economical.

The therapeutic agent for bovine fat necrosis produced in this way is in powder form and is orally administered to cattle as it is or mixed with feed etc. The ingested therapeutic agent is digested in the abomasum without undergoing hydrogenation in the abomasum, and absorbed in the small intestine, since the surface of the lipid is coated with a hard protein film. Eicosapentaenoic acid in the lipids absorbed in this way maintains its physiological activity, so it is highly effective in treating beef fat necrosis.

〔Effect of the invention〕

The therapeutic agent for beef fat necrosis of the present invention coats the surface of lipid particles containing eicosapentaenoic acid with a hardened protein film, so that eicosapentaenoic acid, which is a physiologically active substance, is hydrogenated in the rumen of cattle. It can be digested in the abomasum and absorbed in the small intestine while maintaining its activity, making it possible to effectively treat fat necrosis and being highly safe with no side effects.

〔Example〕

Examples of the present invention will be described below. Correct, % is by weight.

Dissolve 1 kg of glycerin fatty acid ester (monoglyceride) in 80 kg of lipid. The lipid is eicosapentaenoic acid concentrated fish oil (manufactured by NOF Corporation, eicosapentaenoic acid 1).
8.8%, docosahexaenoic acid 12.0%, vitamin E
002% content) was used.

20 kg of protein (casein) is dissolved in 120 Q of warm water, a lipid phase is added, and the mixture is emulsified using a stirrer.

After emulsification, the mixture is homogenized using a homogenizer at a rate of 100 kg/cd in the first stage and 200 kg/cd in the second stage. While stirring in a homogenizer, an aqueous solution of 600 g of a hardening agent (glutaraldehyde) dissolved in 20Q water is added to perform hardening treatment. After sterilization,
Spray drying was carried out at an internal temperature of 90° C. to obtain 77 kg of a powdered therapeutic agent for beef fat necrosis.

As a comparative example, a powder preparation was obtained under the same manufacturing conditions without hardening.

Next, an experiment was conducted using three Holstein cows weighing 110-120 kg, each of which had a cannula attached to its rumen. First, mix feed, hay cubes (formed hay),
Hay, straw (TDN [total digestible nitrogen] 101%,
After feeding on DCP (digestible crude protein) 106% for one month, a treatment agent for beef fat necrosis was administered at a dose of 1 g/kg per body weight per day.
The mice were mixed with compounded feed and administered for 2 months, and then reared for 5 weeks under the conditions before administration, and samples were taken once every week to analyze blood lipid components. As a comparative example, a powdered preparation without hardening treatment was administered under the same conditions. The results are shown in Table 1.

As is clear from Table 1, this therapeutic agent is effectively digested and absorbed by cows without undergoing hydrogenation. In addition, uncured powdered agents have a lower
It is clear that a reaction occurs in the rumen.

Next, we took a look at a black Japanese female adult cow with fat necrosis (weight 410-48
0 kg) Using 6 animals, this therapeutic agent was administered at Ig/kg per body weight,
It was added to the mixed feed and raised. 1 conducted monthly rectal examinations and confirmed the effectiveness of treatment for fat necrosis.

The results are shown in Table 2.

From the above effects, it is clear that the present therapeutic agent for fat necrosis has excellent therapeutic effects.

Agent: Patent attorney Sei Yanagi Hara

Claims (1)

[Claims] (1) Beef fat consisting of particulate lipid containing 5% by weight or more of eicosapentaenoic acid in the fatty acid composition, a protein film that coats the surface of this particulate lipid, and a hardening agent that hardens this protein film. A therapeutic agent for necroptosis.